Wed, Apr. 22, 12:45 PM
Wed, Apr. 22, 9:15 AM
Wed, Apr. 22, 8:50 AM| 14 Comments
Wed, Apr. 15, 12:32 PM
- Beaten-down/well-shorted 3D Systems (DDD +4.6%), Stratasys (SSYS +3.7%), Voxeljet (VJET +4.4%), and Organovo (ONVO +5.2%) are posting big gains. Volume has been slightly above-average for ONVO, normal for DDD and SSYS, and below-average for VJET. The Nasdaq is up 0.5%.
- Meanwhile, 3D printing/manufacturing service provider ARC Group (ARCW +12.1%) is soaring after Brean reiterated a Buy rating, albeit while cutting its target by $13 to $12 (still over 2x yesterday's close). The firm thinks EBITDA margin can rise to 18% by year's end from a current 14%, and to "at least 20%" in 2016. It also thinks improving demand from the firearms could drive upside to its estimates.
- The gains come amid NYC's 3D Print Week conference. Both 3D Systems and Stratasys' MakerBot unit (based in Brooklyn) have large presences. As does 3D printing software vendor Materialise (MTLS +2.5%), which is sponsoring the conference's 3D Print Fashion Show and providing a closing keynote.
- Separately, MakerBot has announced a reseller deal with D&H Distributing, an SMB-focused IT distributor for education, healthcare, government, and manufacturing clients. And Stratasys proper has rolled out a new high-end system (the Objet1000 Plus) said to print parts 40% faster than its predecessor, and at a lower cost.
- Last week: 3D Systems rallies towards $30
Tue, Apr. 7, 4:44 PM| 13 Comments
Tue, Apr. 7, 9:13 AM
Tue, Apr. 7, 8:56 AM
- Organovo (NYSEMKT:ONVO) enters into a research collaboration with L'Oreal USA Products to develop skin tissue models using ONVO's NovoGen Bioprinter and L'Oreal's skin cell technology.
- Under the terms of the agreement, L'Oreal will have the exclusive right to use the skin tissue models for the development, manufacturing, testing, evaluation and sale of non-prescription cosmetic, beauty, dermatology and skin care products and nutraceutical supplements. Organovo retains the right to use the skin tissue models for toxicity and efficacy testing of prescription drugs and for developing and testing surgically transplanted and therapeutic tissues.
- The agreement has three phases: development, validation and commercial supply. The continuation from one phase to the next, at L'Oreal's sole discretion, is contingent on the skin tissue models meeting certain performance criteria. The development and validation phases each require L'Oreal to make an upfront payment and payments for certain deliverables. If the collaboration reaches the commercial phase, the companies will negotiate an exclusive commercial supply agreement which will include license and royalty terms.
- Financial terms are not disclosed.
Wed, Apr. 1, 9:25 AM
- Micro cap Organovo (NYSEMKT:ONVO) is up 10% premarket on average volume in response to its announcement that it presented data on in vitro three-dimensional kidney tissue at the Experimental Biology conference in Boston.
- The 3D tissue, fabricated using the company's NovoGen bioprinter, consists of multiple tissue-relevant cell types arranged to recapitulate the renal tubular/interstitial interface, specifically polarized renal proximal tubular epithelial cells and a living interstitial layer of renal fibroblasts and endothelial cells.
- Analyzing the tissue on a slide under a microscope showed evidence of formation of microvascular structures and stable maintenance of the layered architecture for at least two weeks.
Wed, Apr. 1, 9:13 AM
Fri, Mar. 13, 9:14 AM
Fri, Mar. 13, 8:49 AM
- Regenerative medicine firm Organovo (NYSEMKT:ONVO) is bullish over the prospects of its exVive3D liver tissue product and service, saying it will grow into the "tens of millions" with the potential to reach a top line of $100M+. The company doesn't specify precisely how it will ramp up sales considering that it does not anticipate recognizing any commercial revenue from the liver business until at least fiscal Q1 2016 (ending June 30) despite a fiscal Q3 2015 launch (quarter ended December 31, 2015). Robust market uptake appears elusive.
- CEO Keith Murphy remains undaunted. He says the company's "win rate", the customers who sign a contract after requesting a quote, is over 80%. "We are encouraged that we have a high win rate, that our commercial pricing continues to be supported and that we have received repeat business."
- Research services revenue for fiscal Q3 and for the nine-month period ending 12/31: $139K.
- The company plans to release a 3D kidney tissue product in mid-2016.
- ONVO is up 3% premarket on turnover of 15K shares.
Mon, Mar. 2, 10:14 AM
Fri, Feb. 27, 7:14 PM
- Shortly after CEO Keith Murphy suggested another capital raise is on the way to help his company grow its R&D investments, Organovo (NYSEMKT:ONVO) has filed to raise up to $190M via future stock, debt, and/or warrant offerings. (prospectus)
- The 3D-printed tissue developer had $50M in cash at the end of 2014, and no debt. Shares have fallen to $5.67 AH.
Thu, Feb. 26, 9:29 AM
- In a letter to shareholders, Organovo (NYSEMKT:ONVO) Chairman, CEO and President Keith Murphy outlines the benefits for an expanded strategic focus in order to drive long-term value creation. The broader scope will require a higher level of investment, however, so another capital raise appears to be on the horizon.
- In the last paragraph in his letter, Mr. Murphy attempts to minimize the unpleasant ramifications of dilution to current shareholders by illustrating the increases in ONVO's market cap after each of the three rounds of financing in the company's history. Considering the company's market cap is half of what it was 15 months ago, the ability of a fourth round of financing to drive a comparable increase in enterprise value will require substantial patience from stakeholders.
Mon, Feb. 9, 8:41 AM
Tue, Feb. 3, 10:06 AM
- Organovo (ONVO -4.2%), Proto Labs (PRLB -5.4%), and Arcam (OTCPK:AMAVF -4.9%) have joined 3D Systems, ExOne, and Voxeljet in selling off in the wake of Stratasys' Q4/2014 warning and light 2015 guidance.
- Proto Labs is far from a 3D printing pure-play - the company is a custom-parts maker for industrial prototyping, one that supports 3D printing and other manufacturing techniques. Organovo, as a developer of 3D-printed human tissues, is a very different kind of 3D printing firm than the printer makers.
- Proto Labs' Q4 report arrives on Thursday morning.
ONVO vs. ETF Alternatives
Other News & PR